How about " if you are reading this, you are not dead yet " ? Positive enough for a POS stock like IOC.
In my dealing with her, she came across as a warm and likeable person and very professional.
You can actually get an estimate all on your own. According to the recurrence data, typically recurrence peaks at around 1.5 years after enrollment. ( You can find this on the GALE web page , latest presentation slide 3).
Now the 533 th patient was enrolled Sept 14,2014 and the last patient #758 on April 15, 2015. These group of 225 patients should enter the peak of recurrence starting mid-March, 2016.
Out to 5 years and beyond , the rate of recurrence decreases, so the slow enrolment between 2011 to 2013 , if indeed it occurred, has much less impact on the rate as the latest group of 225 patients.
3rd Qtr report was Nov 5,2015.
A question: What is " Impairment of oil and natural gas properties" ? Was that impairment a one time thing ?
That is just BS. Blackjack holds so many stocks, GALE is peanut to them. That is a ridiculous way to accumulate GALE shares.
To the person who give a thumb down, I definitely will write to Joe Biden and my congressman after the 70th event. Count on it.
Specifically, ask Joe Biden of Cancermoonshot to
(1) investigate the shorting practice of GALE
(2) have a talk with the FDA about Neuvax
I think we should send Joe Biden the post or something like that to make him aware of the plight small biotechs are facing. While he cannot change the landscape of shorting over night, may be he can do something about GALE if we made him aware of how close the shorts are getting to kill off GALE's Neuvax and FBP.
Can you ask them to present to their investors a plan of how they will fund GALE between 2017- mid 2018 ? If their plan is credible I think the shorts will melt away.
Ask them why would they chose to start new projects now when they may not even have enough to finish what is at hand.
I don't think you can calculate that way because not all 758 patients were recruited simultaneously in January 20013. (See the patient recruitment data summarised in Fuji's article.)